ROCKVILLE, Md., July 7, 2015 /PRNewswire-USNewswire/ -- Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in Oncology, Vaccines, and General Medicine announced the completion of enrollment and delivery of the final locked database to Heron Therapeutics, Inc. for the Phase 3 trial of its 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the IV NK1 receptor antagonist fosaprepitant and IV corticosteroid dexamethasone for the prevention of delayed chemotherapy induced-nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC), in 14 months from opening the trial.
The Phase 3 trial, known as the MAGIC trial, randomized over 900 patients undergoing HEC treatment for various tumor types and is the only Phase 3 clinical trial CINV in a HEC population performed to date to use as a comparator the currently recommended, standard-of-care, three-drug regimen: a 5-HT3 receptor antagonist (in this case ondansetron), fosaprepitant, and dexamethasone. The trial's primary endpoint of Complete Response, defined as no emesis and no rescue medications during the delayed phase of CINV, (24-120 hours) following administration of HEC agents, was statistically significant in favor of the SUSTOL group (64.7% vs. 56.5%, p=0.014).
"We would like to commend the team at Accelovance for rapidly providing to Heron a cleaned and locked database following treatment of the last patient in the MAGIC trial. The contribution of Accelovance has helped us with our goal of resubmitting our New Drug Application (NDA) for SUSTOL to the US Food and Drug Administration (FDA) by mid-2015," commented Barry D. Quart, PharmD, Chief Executive Officer of Heron Therapeutics.
Accelovance was selected by Heron to provide project management, clinical monitoring, data management, and medical monitoring CRO services for the MAGIC trial. Stephen J. Trevisan, Accelovance's President and CEO commented, "Our talented CRO team members have enjoyed supporting the Heron team and contributing to the advancement of SUSTOL for CINV. We're proud to have been a part of this trial and to know that, pending FDA review and approval, there may soon be a new option for patients suffering from chemotherapy-induced nausea and vomiting."
Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning Contract Research Organization (CRO) focused primarily in Oncology, Vaccines, and General Medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and Clinical Engagement Solutions utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at www.accelovance.com.
Press Contact: Michael Keens, VP Business Development